Wells Fargo analyst Larry Biegelsen maintained a Hold rating on Axonics Modulation Technologies (AXNX – Research Report) yesterday and set a price target of $71.00. The company’s shares closed yesterday at $68.27.
According to TipRanks, Biegelsen is a 5-star analyst with an average return of 11.7% and a 61.57% success rate. Biegelsen covers the Healthcare sector, focusing on stocks such as Abbott Labs, Bausch + Lomb Corporation, and Boston Scientific.
Currently, the analyst consensus on Axonics Modulation Technologies is a Hold with an average price target of $71.00.
AXNX market cap is currently $3.51B and has a P/E ratio of -535.44.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Axonics Modulation Technologies (AXNX) Company Description:
Axonics Modulation Technologies, Inc. operates as a medical technology company, which engages in the design, development, and commercialization of sacral neuromodulation solutions. The firm focuses on the treatment of patients with overactive bladder (OAB), fecal incontinence (FI), and urinary retention (UR). It offers rechargeable SNM system, which delivers mild electrical pulses to the targeted sacral nerve in order to restore normal communication to and from the brain to reduce the symptoms of OAB, FI, and UR. The company was founded by Guang Qiang Jiang, Danny L. Dearen, Timothy Deer, and Michael V. Williamson in March 2012 and is headquartered in Irvine, CA.
